Tianyong Hu

Tianyong Hu

Auto-generated profile, based on publicly available information

Tianyong Hu

Shenzhen Otolaryngology Research Institute

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
PLPeng Liu
Peng Liu
THTianyong Hu
Tianyong Hu
CKChenglin Kang
Chenglin Kang
JLJiangqi Liu
Jiangqi Liu
JZJin Zhang
Jin Zhang
SQShuqi Qiu
Shuqi Qiu
Allergic rhinitis (AR) impairs the quality of life of patients and reduces the efficiency of social work, it is an increasingly serious public medical and economic problem in the world. Conventional anti-allergic drugs for the treatment of allergic rhinitis (AR) can cause certain side effects, which limit the quality of life of patients. Therefore, it makes sense to look for other forms of treatment. Several studies in recent years have shown that probiotics have shown anti-allergic effects in various mouse and human studies. For example, the application of certain probiotic strains can effectively relieve the typical nasal and ocular symptoms of allergic rhinitis in children and adults, thereby improving the quality of life and work efficiency. At the same time, previous studies in humans and mice have found that probiotics can produce multiple effects, such as reduction of Th2 cell inflammatory factors and/or increase of Th1 cell inflammatory factors, changes in allergy-related immunoglobulins and cell migration, regulate Th1/Th2 balance or restore intestinal microbiota disturbance. For patients with limited activity or allergic rhinitis with more attacks and longer attack duration, oral probiotics have positive effects. The efficacy of probiotics in the prevention and treatment of allergic rhinitis is remarkable, but its specific mechanism needs further study. This review summarizes the research progress of probiotics in the treatment of allergic rhinitis in recent years.

1 February 2021 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
THTian-Yong Hu
Tian-Yong Hu
HZHua Zhang
Hua Zhang
YCYan-Yan Chen
Yan-Yan Chen
WJWei-Hua Jiao
Wei-Hua Jiao
JFJun-Ting Fan
Jun-Ting Fan
BCBaohui Cheng
Baohui Cheng
Background: Marine natural products harbor a variety of pharmacological activities, and the sea species have been becoming a main source of new drug candidate. In pursuit of safer and more effective anti-inflammation drug, the anti-inflammatory activities, anti-oxygenation effects and underlying molecular mechanisms of compound dysiarenone from Dysidea arenaria were investigated via LPS-induced RAW 264.7 cell model. Methods: Firstly, RAW 264.7 cells have been stimulated with LPS and treated with dysiarenone, and the cell viability of the LPS-treated RAW 264.7 cells was examined. One-step method, DCFH-DA fluorescence probe method was used to detect reactive oxygen species (ROS). The modulation of dysiarenone on anti-inflammation was detected by enzyme-linked immunosorbent assay by measuring the release of inflammatory cytokines (TNF-α and IL-6), and inflammatory mediators (LTB4). Further, the underlying anti-inflammatory mechanism of dysiarenone was explored by determining the expression of inducible 5-LOX, MAPKs, p-Akt, and p-NF-κB p65. Oxidative stress is tightly connected with inflammation, which was also evaluated through nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (OH-1) signaling pathway. Results: Our study unraveled that dysiarenone between 2 and 8 μM reduces the inflammation responses via suppressing the production of inflammatory cytokines (TNF-α and IL-6) and inflammatory mediators (LTB4). Dysiarenone down-regulated the protein levels of inducible 5-LOX via the inhibition of phosphorylation of MAPKs (including p38, ERK), Akt and NF-κB p65. Additionally, dysiarenone decreases ROS accumulation by upregulating HO-1 expression via nuclear translocation of Nrf2. Conclusion: In conclusion, we demonstrated that dysiarenone possesses anti-inflammation and anti-oxidation activity via inhibiting 5-LOX/NF-κB/MAPK and Nrf2/HO-1 signaling pathway. Dysiarenone might be a promising lead compound for inflammatory diseases.

21 October 2019 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
WHWenhui Hu
Wenhui Hu
LMLi Ma
Li Ma
GYGui Yang
Gui Yang
XZXianhai Zeng
Xianhai Zeng
JLJiangqi Liu
Jiangqi Liu
ZLZhiqiang Liu
Zhiqiang Liu
Allergic rhinitis (AR) is a common disease that requires more convenient, safe and effective antigen-specific immunotherapies. The present study aimed to investigate the therapeutic effect of intranasal administration of a eukaryotic expression vector co-expressing Der p2 and A20 protein (pVAX1-Der p2-A20) on mice with allergic rhinitis. The pVAX1-Der p2-A20 vaccine was prepared and encapsulated into poly(L-lactide-co-glycolide) (PLGA) nanoparticles. An allergic rhinitis Balb/c mouse model was established through intraperitoneal sensitization with recombinant Der p2 and cholera toxin followed by intranasal challenge with recombinant Der p2. The treatment effect of the DNA vaccine on nasal allergic inflammation was evaluated, and serum IgE, sIgE, IgG and cytokine levels were determined by ELISA. The percentage of CD4(+)CD25(+)Foxp3(+)Tregs in the spleen was detected by flow cytometry. The DNA vaccine co-expressing Der p2 and A20 was successfully constructed and encapsulated into PLGA nanoparticles. Der p2-A20 DNA vaccine intranasal administration markedly ameliorated Der p2-induced nasal allergic inflammation. The serum Der p2-specific IgE, IL-4 and IL-13 expression levels were inhibited, while the Der p2-specific IgG1, IgG2a and IFN-gamma expression levels in the serum and splenic CD4(+)CD25(+)Foxp3(+)Treg population were significantly increased after Der p2-A20 DNA vaccine treatment. These results indicated that the Der p2-A20 DNA vaccine alleviates nasal allergic inflammation and promotes splenic Treg population in mice with allergic rhinitis.

4 February 2019 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
JXJin‐Mei Xue
Jin‐Mei Xue
MZMei‐Zhen Zhao
Mei‐Zhen Zhao
FMFei Ma
Fei Ma
SLShan‐Shan Li
Shan‐Shan Li
LMLi‐Hua Mo
Li‐Hua Mo
PYPingchang Yang
Pingchang Yang

7 January 2021 in Journal of Bioenergetics and Biomembranes
Verified
Journal Article
Closed access
PDF file
HCHanrong Cheng
Hanrong Cheng
LCLi Chen
Li Chen
YWYongli Wei
Yongli Wei
THTianyong Hu
Tianyong Hu
DLDongcai Li
Dongcai Li
BWBenqing Wu
Benqing Wu

1 January 2019
Verified
Journal Article
Closed access
CZCai-Jie Zhou
Cai-Jie Zhou
FMFei Mae
Fei Mae
WLWen-Jing Liao
Wen-Jing Liao
LSLi-Juan Song
Li-Juan Song
DYDian Yu
Dian Yu
PYPingchang Yang
Pingchang Yang